How does rasagiline (a selective monoamine‑oxidase‑B inhibitor) aid in treating Parkinson disease?

How Rasagiline Helps in Treatment of Parkinson's Disease

Rasagiline is a selective, irreversible MAO-B inhibitor that treats Parkinson's disease by blocking the breakdown of dopamine in the brain, thereby increasing dopamine availability in the striatum to improve motor symptoms and reduce motor fluctuations. 1

Mechanism of Action

Rasagiline works through irreversible inhibition of monoamine oxidase type B (MAO-B), the enzyme responsible for metabolizing dopamine in the brain 1. By blocking this enzyme:

• Extracellular dopamine levels increase in the striatum, the brain region most affected in Parkinson's disease
• The elevated dopaminergic activity mediates improvements in motor dysfunction
• Unlike the older MAO-B inhibitor selegiline, rasagiline is 5-10 times more potent and is not metabolized to amphetamine derivatives 2, 3

The drug achieves >90% MAO-B inhibition within 3 days of daily dosing at therapeutic doses 1.

Clinical Efficacy Across Disease Stages

Early Parkinson's Disease (Monotherapy)

For patients with early PD not yet requiring levodopa, rasagiline 1 mg daily significantly slows symptom progression. In a 26-week randomized controlled trial of 404 patients:

• Rasagiline 1 mg reduced total UPDRS scores by 0.1 points from baseline versus a worsening of 3.9 points with placebo (p=0.0001) 1
• The adjusted effect size was -4.20 points (95% CI: -5.66 to -2.73) compared to placebo 3
• Patients had an average disease duration of only 1 year 1

A critical finding suggests potential disease-modifying effects: Patients who started rasagiline immediately had less functional decline at 12 months than those whose treatment was delayed by 6 months, even after both groups had received 6 months of active treatment 4. This divergence in outcomes cannot be explained by symptomatic effects alone.

Advanced Parkinson's Disease (Adjunct to Levodopa)

For patients with motor fluctuations despite levodopa therapy, rasagiline 1 mg daily reduces "off" time by approximately 1 hour per day. In the PRESTO study of 472 patients:

• Rasagiline 1 mg reduced daily "off" time by 1.85 hours (29%) versus 0.91 hour (15%) with placebo 5
• The difference versus placebo was 0.94 hour less off time per day (p<0.001) 1
• Rasagiline 0.5 mg provided intermediate benefit with 0.49 hour reduction versus placebo 5

The efficacy of rasagiline 1 mg was comparable to entacapone 200 mg taken with each levodopa dose 4.

Adjunct to Dopamine Agonists (Without Levodopa)

In patients on stable dopamine agonist therapy but with inadequate symptom control, rasagiline 1 mg as adjunct therapy reduced total UPDRS scores by 3.6 points versus 1.2 points with placebo (p=0.034) 1.

Dosing Strategy

The recommended dosing depends on disease stage and concomitant medications:

• Monotherapy or adjunct without levodopa: Start with 1 mg once daily 1
• Adjunct to levodopa: Start with 0.5 mg once daily, increase to 1 mg if needed for clinical response 1
• With CYP1A2 inhibitors (e.g., ciprofloxacin): Maximum 0.5 mg daily due to 2-fold increase in rasagiline exposure 1
• Mild hepatic impairment: Maximum 0.5 mg daily; contraindicated in moderate-to-severe hepatic impairment 1

Rasagiline can be taken with or without food, though high-fat meals reduce Cmax by 60% without significantly affecting overall exposure 1.

Additional Benefits Beyond Motor Symptoms

Sleep Disorders

Rasagiline may improve sleep parameters in PD patients. A 12-week study showed that adding rasagiline 1 mg to levodopa significantly reduced sleep latency (p<0.001) and increased total sleep time (p=0.002) compared to levodopa alone 6. This effect may relate to increased melatonin levels in the pineal gland 6.

Potential Neuroprotection

Beyond symptomatic relief, rasagiline demonstrates neuroprotective properties in experimental models that appear independent of MAO-B inhibition 7:

• Prevents mitochondrial permeability transition and subsequent apoptotic cascades
• Increases expression of prosurvival genes and neurotrophic factors (GDNF)
• The delayed-start trial design suggests possible disease modification in humans 4

However, definitive proof of neuroprotection in clinical practice remains under investigation 3.

Important Safety Considerations

At recommended doses (≤1 mg daily), rasagiline maintains selectivity for MAO-B and does not require dietary tyramine restriction 1. However:

• Foods with very high tyramine content (≥150 mg) like aged Stilton cheese could potentially cause hypertensive reactions 1
• Contraindicated with: meperidine, tramadol, methadone, dextromethorphan, SSRIs/SNRIs (risk of serotonin syndrome), other MAO inhibitors 1
• May cause or worsen dyskinesia when added to levodopa—reduce levodopa dose if this occurs 1
• Can cause orthostatic hypotension, particularly in combination with levodopa 1

Clinical Algorithm for Use

Start rasagiline 1 mg daily in early PD before levodopa is needed, as this may provide long-term benefits beyond symptomatic improvement.

For patients already on levodopa with motor fluctuations, add rasagiline 0.5 mg daily and titrate to 1 mg based on response. Expect approximately 1 hour reduction in daily "off" time. If dyskinesia emerges or worsens, reduce the levodopa dose rather than stopping rasagiline.

Monitor for: orthostatic hypotension (especially first few weeks), dyskinesia, impulse control disorders, and hallucinations (particularly in elderly or cognitively impaired patients).

The drug's irreversible MAO-B inhibition means effects persist for at least 1 week after discontinuation 1, which is clinically relevant when switching medications or managing drug interactions.